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Abstract 
We describe that galectin-1 is a receptor for the angiogenesis inhibitor anginex and that the 
protein is crucial for tumor angiogenesis. Galectin-1 is overexpressed in endothelial cells of 
different human tumors. Expression knockdown in cultured endothelial cells inhibits cell 
proliferation and migration. The importance of galectin-1 in angiogenesis is illustrated in the 
zebrafish model, where expression knockdown results in impaired vascular guidance and growth 
of dysfunctional vessels. The role of galectin-1 in tumor angiogenesis is demonstrated in 
galectin-1 null mice, in which tumor growth is markedly impaired due to insufficient tumor 
angiogenesis. Furthermore, tumor growth in galectin-1 null mice no longer responds to anti-
angiogenesis treatment by anginex. Thus, galectin-1 regulates tumor angiogenesis and is a target 
for angiostatic cancer therapy. 
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Introduction 
 An adequate vasculature is a prerequisite for tumors to grow, and the need for neovessel 
formation (or angiogenesis) provides a target for treatment of cancer (1). Endothelial cells (EC) 
that line the tumor vasculature are particularly suitable target cells for therapeutic approaches 
since they are easily accessible to agents delivered via the blood (2). However, to affect only 
tumor vasculature, specific targets on angiogenically active EC are essential. To date, only a few 
targets of tumor vasculature have been identified (3). 
 We recently developed the specific angiostatic peptide anginex that inhibits tumor growth 
through specific inhibition of angiogenesis (4-6). Although a broad profile of activities of 
anginex is known, such as prevention of EC adhesion and induction of apoptosis, the molecular 
target on tumor EC was never identified. In a receptor finding study using a yeast two-hybrid 
screening approach, we identified galectin-1 as a target protein of anginex. 
 Galectin-1 belongs to a family of carbohydrate binding proteins that share a conserved 
carbohydrate recognition domain (CRD) of approximately 130 amino acids (7-9). Over a dozen 
mammalian galectins have been described (10, 11) and members of this family are expressed in a 
wide range of species, suggesting an important role for galectins in basic cellular mechanisms. 
Galectins can be secreted, and depending on the cell type or state of differentiation, they have 
been found in the nucleus, in the cytoplasm, or in the extracellular matrix. It has been proposed 
that galectin-1 mediates cell adhesion and migration (12), and is involved in several processes 
including proliferation (13), apoptosis (14), and even mRNA splicing (15). The role of galectin-1 
in EC function or in vascular biology has not been extensively studied. 
Here, we describe the function of galectin-1 in the angiogenesis. We provide direct functional 
evidence that galectin-1 is required for tumor angiogenesis and for outgrowth of tumors. 
Furthermore, we show that galectin-1 is the target for the potent angiogenesis inhibitor anginex, 




Galectin-1 binds the angiostatic peptide anginex. 
The goal of the present study was to identify the receptor of anginex, an angiogenesis inhibitor 
which has previously been shown to specifically target tumor endothelial cells (EC) (5). 
Immunohistochemistry revealed vesicular uptake of anginex by EC within 2 hours (Fig. 1A). 
Electron microscopy showed anginex located at the membrane of intracellular vesicles, 
suggesting receptor-mediated uptake (Fig. 1B). To identify this receptor, yeast two-hybrid (Y2H) 
analysis was performed. To that end, the recently described artificial anginex gene (16) was 
cloned in frame with the GAL-4 DNA binding domain of the Y2H bait vector pGBDT7, which 
was confirmed by Western blotting (not shown). Multiple screens against cDNA libraries of 
activated EC identified galectin-1 (gal-1) as the receptor for anginex (Suppl. Table 1/Suppl. Fig. 
1) which was independently confirmed using three approaches. i) Double staining of anginex 
treated EC showed co-localization of anginex and gal-1. ii) Analysis of NMR spectra revealed 
chemical shift changes of certain resonances from gal-1 upon addition of anginex, indicative of a 
specific molecular interaction. iii) Plasmon resonance spectroscopy (BIAcore analysis) was used 
to further define the kinetics and stoichiometry of the interaction. Analysis of the binding kinetics 
revealed a 1:1 Langmuir association with a rate constant (ka) of ~6.5x103 Ms-1, while the 
dissociation kinetics followed a biphasic pattern with dissociation rate constants of 4.2x10-2 s-1 
and 5.9x10-4 s-1, respectively. These data suggest that dimerized anginex binds to gal-1 and that 
subsequently the two anginex molecules dissociate as monomers with a Kd of 6.4 μM for 
dissociation of first anginex molecule and a Kd of 90 nM for the second molecule. This result is 
supported by mass spectrometry which displayed a major peak with a mass of 22.8 kD (gal-1 
monomer (14.7 kD) + anginex dimer (8 kD) (not shown). The data above show that gal-1 and 
anginex interact, suggestive of gal-1 serving as receptor for anginex.  
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Galectin-1 is overexpressed in tumor EC; a crucial role in EC proliferation and migration. 
To determine the role of gal-1 in tumor EC biology, we first analyzed gal-1 expression in human 
tumor blood vessels by immunohistochemistry. While gal-1 is only weakly expressed in EC of 
normal tissue (colon is shown: Figure 1C, left panels), a strong expression was found in EC of 
human colon carcinoma (Figure 1C, middle panels) and breast carcinoma (not shown), 
especially in EC that stained positive for the proliferation marker Ki67. Similar results were 
observed for a sarcoma type of tumor (Ewing sarcoma) in which the gal-1 staining was almost 
exclusively observed in vessels (Figure 1C, right panels). These data demonstrate that the 
amount of gal-1 protein is upregulated in angiogenically active EC. Indeed, growth factor 
activation of freshly isolated human umbilical vein EC resulted in a significant increase in gal-1 
mRNA expression and a concomitant >10-fold induction of gal-1 protein expression (Figure 
1D). Furthermore, treatment of activated EC with a gal-1 specific antisense oligodeoxynucleotide 
(ODN) resulted in inhibition of EC proliferation, while a random ODN had no effect (Figure 
1E). Next to EC proliferation, EC migration was also inhibited by treatment with either the gal-1 
specific ODN (Figure 1F) or the rabbit polyclonal anti-gal-1 antibody (Figure 1G). These data 
strongly suggest a role for gal-1 in EC biology. 
 
Galectin-1 is required for coordinated angiogenesis in vivo. 
The role of gal-1 in angiogenesis in vivo was first studied in the chick chorioallantoic membrane 
(CAM). Treatment of the CAM with a rabbit polyclonal anti-gal-1 antibody induced a significant 
inhibition of microvessel density, similar as previously published for anginex (4-5) albeit less 
pronounced. Interestingly, treatment caused tortuous and irregular growth of the vessels, 
suggesting a defect in vascular guidance (Suppl. Fig. 2). For further insight in the role of gal-1 
during angiogenesis in vivo, we used the Tg(fli1:egfp)y1 zebrafish model. In this model, EC are 
marked by expression of green fluorescent protein (GFP) (17). Recently, 3 prototype galectins 
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were described in zebrafish (Lgals1-L1/L2/L3) of which Lgals1-L2 was found to preferentially 
bind N-acetyllactosamine, similar to human gal-1 (18). Since Lgals1-L1 is not expressed during 
embryogenesis (18) we only studied the role of the other two prototype galectins in vascular 
development. Whole mount RNA in situ hybridization at 48 hours post-fertilization revealed 
specific expression of Lgals1-L2 in the eyes around the lens and in the ventricular zone in the 
head (Figure 2A). Lgals1-L3 expression was broader and largely overlapped with that of Lgals1-
L2 (Figure 2B). Furthermore, cross sections at the level of the midbrain showed co-localization 
of both Lgals1-L2/-L3 and the EC specific marker VE-cadherin in the retinal vessels (Figures 
2C-E) and in the blood vessels in the brain (not shown).  
To determine the function of Lgals1-L2 and -L3 on vascular development, morpholino-modified 
antisense oligonucleotides (MOs) were designed to specifically target either the translation start 
site (ATG-MO) or the splice donor site (splice-MO). We verified that injection of each splice-
MO successfully interfered with the splicing of the respective transcripts (not shown). Injection 
of either Lgals1-L2 or -L3 ATG-MO induced hemorrhages in the head and in/behind the eyes of 
the embryos at 2.5 days post fertilization, as detected with a sensitive o-Dianisidine blood 
staining. Co-injection of both Lgals1-L2 and -L3 MOs resulted in even more severe hemorrhages 
(Figures 3A-D). Similar results were observed with the splice-MOs (not shown). Confocal 
scanning laser microscopy in the ventricular zone of Tg(fli1:egfp)y1 zebrafish revealed vascular 
defects, at the location of the hemorrhages, after co-injection of Lgals1-L2 and -L3 ATG MO. 
Compared to untreated zebrafish (Figure 3F), abnormal sprouting and misguidance of vessels 
clearly appeared in the mid-cerebral area of the Lgals1-L2 and -L3 ATG MO treated animals 
(Figures 3E-H). Vascular network formation of the middle cerebral-, dorsal longitudinal-, 
mesencephalic- and anterior cerebral veins was also distorted by both MOs, and most severely in 
the double knockdown (Figure 3G). The same defects were observed upon co-injection of both 
splice MOs, indicating specificity of the knockdown defects (Figure 3H), while single injection 
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of each splice MO revealed weaker defects (not shown). Similar to those in the ventricular zone, 
retinal vessels showed abnormal sprouting and growth in the regions where hemorrhages 
occurred (not shown). Together with observations from the CAM, results in zebrafish indicate 
that gal-1 is important in vivo for coordinated vessel outgrowth and vascular network formation. 
 
Galectin-1 facilitates tumor progression through angiogenesis. 
The presented results urged us to study the role of gal-1 by analyzing tumor angiogenesis in the 
gal-1 null mice (19). To compare tumor growth in the presence or absence of gal-1, wild type 
(gal-1+/+) and null (gal-1-/-) mutant 129P3/J mice were subcutaneously injected with syngeneic 
murine F9 teratocarcinoma cells. Three days after injection, a small palpable tumor developed in 
all mice, suggesting that tumor initiation and initial growth is not dependent on gal-1. However, 
subsequent tumor growth was significantly abrogated in the gal-1-/- mice compared to the wild-
type animals. Fifteen days after injection, the tumor volumes in the gal-1-/- mice were 
approximately 4-fold smaller compared to those in the gal-1+/+ mice (Figure 4A). As expected, 
immunohistochemical analysis showed high expression of gal-1 in the EC of tumor vessels in the 
wild-type animals and no expression in the null mice (Figure 4B). Quantification of microvessel 
density revealed a significant lower amount of blood vessels in null mice compared to wild-type 
mice (Figure 4C). In addition, parameters of vessel architecture were decreased (Suppl. Table 
2). Since gal-1 has been shown to mediate apoptosis in activated T cells, which could contribute 
positively to tumor growth (20), we also quantified the amount of peripheral blood leukocytes, 
and the presence of CD45+ and CD8+ cells in the tumors. There was no significant difference in 
these parameters between gal-1+/+ and gal-1-/- animals (Suppl. Fig. 3) which strongly suggests 




Galectin-1 is a target protein for angiostatic therapy. 
Because gal-1 was initially identified as a receptor for the angiostatic peptide anginex, we also 
analyzed the effect of anginex treatment in wild type and gal-1 null mice. In wild-type animals, 
anginex significantly inhibited tumor growth by approximately 70% (Figure 4D) and vessel 
density by approximately 55% (Figure 4E), which is comparable with previous observations for 
anginex in other tumor models (5, 21). In gal-1-/- mice, treatment with anginex had no effect on 
tumor growth (Figure 4F). In addition, anginex treatment did not significantly affect the number 
of infiltrating CD45+ or CD8+ cells in the tumors of both the wild type and null mice (Suppl. Fig. 
4). These data demonstrate that gal-1 mediates the angiostatic activity of anginex and that gal-1 
can serve as a target for angiostatic therapy.  
 8
Discussion 
 The current study is the first to demonstrate that gal-1 is important in tumor angiogenesis 
and that targeting of gal-1 can be an efficient angiostatic therapeutic strategy. Previous studies 
have shown that gal-1 is key in two mainstays of cancer. Firstly, gal-1 supports metastasis 
formation, because it facilitates interactions between tumor cells and endothelial cells (EC) (22, 
23). Secondly, it protects the tumor against immunity since it can induce apoptosis in tumor 
infiltrating cytotoxic leukocytes (14, 20). This study now reports a critical role in angiogenesis, a 
third important pillar in tumor growth. Our results reveal a direct role of gal-1 in EC biology. We 
found a direct involvement of gal-1 in EC proliferation and migration in vitro and in tumor 
angiogenesis in vivo. While the angiogenesis-independent onset of F9 tumor growth was similar 
in gal-1 null and wild type mice, the angiogenesis dependent outgrowth of tumors was severely 
hampered in the null mice. The low microvessel density in the null mice led us to conclude that 
the abrogated tumor growth is caused by inefficient angiogenesis. It has been shown that gal-1 
null mice have subtle neuronal abnormalities that become apparant upon challenge (24, 25). In 
line with this, the effect on angiogenesis also becomes apparent by challenging the mice with a 
growing tumor. This corroborates with our observations in the CAM and the zebrafish, in which 
acute interference with gal-1 function also results in aberrant angiogenesis. Obviously, the 
presence of gal-1 is required for a proper response to an acute stress or pressure on EC biology 
and angiogenesis. It remains to be investigated whether vascular development in the null mice is 
indeed normal, or that subtle vascular defects do exist. 
 We also observed that intervening with gal-1 function results in irregular patterning of the 
vasculature. The abnormal vessel architecture in the CAM, the zebrafish model, and in knockout 
mice tumors, suggest that gal-1 is involved in vascular network formation. Recent studies have 
shown that the development of both vascular and neuronal networks is regulated by the same 
receptor/ligand pairs, i.e. Robos/Slits, Ephrins/Eph receptors, Neuropilins/Semaphorins, and 
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Netrins/Unc5B (26, 27). Interestingly, for gal-1 a role in neuronal pathfinding has already been 
identified (28). Furthermore, gal-1 null mice show neuronal abnormalities in adulthood (25). 
Together with the role of gal-1 in angiogenesis described here, these data strongly suggest that 
gal-1, as well as other members of the galectin family (galectin-3 (29, 30)) are also involved in 
both neuronal and vascular development. 
 It has been proposed that galectins can serve as molecular targets for cancer therapy (20, 
31-33). Interestingly, we identified gal-1 as a receptor for the angiostatic peptide anginex. 
Anginex has been shown to inhibit tumor growth by inhibition of tumor angiogenesis (4-6). A 
previous study reported that transport to the tumor vasculature is facilitated by fibronectin (34). 
Our results now show that for the angiostatic activity on EC, galectin-1 is required. Anginex 
treatment in gal-1 null mice did not result in further inhibition of the already hampered tumor 
growth, while wild type mice responded as reported previously (5, 6). This indicates that gal-1 is 
essential for the activity of anginex and that gal-1 can indeed serve as a target for angiostatic 
cancer therapy. We also observed high expression of gal-1 in EC in mouse tumors as well as in 
human colon and breast carcinomas. There are other reports on the expression of gal-1 in tumor 
stroma, mainly in studies comparing the expression between normal and cancerous tissues 
(reviewed by (33)). Elevated stromal expression of gal-1 has been reported in several cancers 
including cancer of the ovaries (35), breast (36), prostate (37), and colon (38). These results 
suggest that the increased expression in tumors makes the protein an excellent target for 
diagnostic or therapeutic purposes.  
 It is attractive to speculate that, since gal-1 is crucial in several prerequisites for unlimited 
tumor growth, gal-1 targeting compounds may have multimodal activities. Interfering with gal-1 
function could (i) prevent metastasis formation through inhibition of gal-1 facilitated tumor cell-
EC interactions (22, 23), (ii) abrogate tumor escape from immunity through blockade of gal-1 
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induced apoptosis in activated T lymphocytes (14, 20), and (iii) prevent the execution of tumor 
angiogenesis (this study). This makes gal-1 an excellent target for cancer therapy. 
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Materials and Methods 
 
Cell cultures  
Human umbilical vein EC (HUVEC) and the human microvascular EC line HMEC were cultured 
as described elsewhere (5). F9 teratocarcinoma cells (kind gift from Dr. H. Weich) were cultured 
in RPMI-1640 supplemented with 10% fetal bovine serum, 1% glutamin, 50 U/ml penicillin, and 
50 ng/ml streptomycin. 
 
Mouse tumor model 
A total of 14 adult 129P3/J gal-1-/- mutant mice (19) and 17 matched 129P3/J gal-1+/+ (wild type) 
mice were used in this study. On day 1, animals were injected s.c. with 3x106 syngeneic F9 
teratocarcinoma cells. On day 7, anginex treatment (10 mg/kg/day) was started in 7 wild type and 
9 mutant mice by daily i.p. injections. Tumor volume and mouse weight were measured daily 
throughout the experiment. Animals were given water and standard chow ad libitum, and they 
were kept on a 12-hour light/dark cycle. All experiments were approved by the local ethical 
review committee. 
 
Knockdown of galectin-1 expression in vitro 
Knockdown of gal-1 expression in vitro was obtained using a gal-1 specific antisense 
oligodeoxynucleotide (hgal1 ODN: GTCACCGTCAGCTGCCATGT). As control, a random 
nonspecific antisense oligodeoxynucleotide (control ODN: TCCCTAGTGACTCTTCCC) was 




FACS analysis of gal-1 protein expression was performed on ethanol fixed HUVEC. Cells were 
washed in 0.1% BSA/0.01% sodium azide/PBS, incubated on ice with polyclonal rabbit anti-
galectin antibody (39), and washed with PBS. Next, the cells were incubated with FITC-labeled 
polyclonal goat anti-rabbit Ig antibody (Dako) and washed with PBS. Five thousand events were 
acquired for each sample on a FACSCalibur flow cytometer (Beckton Dickinson). All 
experiments were performed in triplicate. 
 
Migration, proliferation, and CAM assay 
Migration, proliferation, and CAM assays were performed as described elsewhere (16). Within 
each proliferation experiment, treatments were done in triplicate and all proliferation and 
migration experiments were performed at least three times. For the CAM, two independent 
experiments were performed (overall n = 13 / treatment group). 
 
Real-time PCR 
Total RNA isolation, subsequent cDNA synthesis, and real-time PCR were performed as 
described previously (40) with primers targeted against human gal-1 (Forward: 
TGCAACAGCAAGGACGGC; Reverse: CACCTCTGCAACACTTCCA). Primers were 
purchased from Eurogentec and experiments were performed in triplicate. 
 
Immunohistochemistry 
Immunohistochemical staining of anginex uptake was performed on HUVEC cytospins. Cells 
were acetone fixed and air dried. Following incubation in 1% paraformaldehyde cells were 
incubated in fetal calf serum after which mouse 2D10 monoclonal anti-anginex antibody (5) was 
applied in 0.05% Triton X100/PBS. Following incubation with Texas Red labeled goat-anti-
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mouse Ig antibody, the cells were washed with PBS and mounted in Immumount (Shandon Inc.) 
supplemented with 1 µg/ml 4',6-diamidino-2-phenylindole (DAPI; Molecular Probes). In the 
negative control, incubation with the first antibody was omitted. 
Doublestaining for Ki67 and CD31/34 on paraffin-embedded tissue sections was performed as 
previously described (41). Tissues from normal colon, colon carcinoma, and Ewing sarcoma were 
obtained from the stocks of the Department of Pathology, University Hospital Maastricht. For 
gal-1 staining, paraffin-embedded tissue sections were dewaxed and endogenous peroxidase 
activity was blocked with 0.3% H2O2 in methanol. Next, the slides were microwave pretreated in 
citric acid. After blocking with 1% BSA/PBS primary antibody was applied in 0.5%BSA/PBS. 
Next, biotin-labeled secondary antibody was applied and staining was performed with the 
StreptABComplex/HRP kit (Dako) according the suppliers protocol. The tissue sections were 
counterstained with haematoxilin (Merck), dehydrated and mounted in Entellan (Merck). The 
same protocol was used for EC staining with the EC specific antibody 9F1 (42). Staining for 
CD45+ and CD8+ cells was performed on frozen tissue sections which were fixed in acetone and 
air dried. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxidase/PBS and 
aspecific binding was blocked with 20% FCS/0.1% Tween20/PBS. Next, the primary antibody 
(MP33 rat anti-mouse CD45 or 53.6.27 rat anti-mouse CD8) was applied, followed by incubation 
with biotin labeled secondary antibody. Staining was visualized using the Vectastain ABC kit 
(Vector Laboratories) and subsequently, sections were counterstained with haematoxylin, 
dehydrated, and mounted with Entellan. Within each section, the number of positive cells was 
scored at 4 different locations in a blinded fashion by two different observers. Fluorescent 
staining of CD31 in murine tumors and subsequent scoring of vessel characteristics was 





For in vivo experiments, the previously described Tg(fli1:egfp)y1 zebrafish was used (17). Knock-
down of Lgals1-L2 and -L3 expression was achieved by injection of specific morpholino-
modified antisense oligonucleotides (MOs; Genetools) into 1-cell stage embryos (43). The 
following MOs were used: Lgals1-L2 ATG-MO, 5'-GTATAAGCACACCGGCCATTTTGAC-3'; 
Lgals1-L3 ATG-MO, 5'-AAGATCCCAGGCTAAGGACGTCATT-3'; Lgals1 L2 splice-MO, 5'-
TTGTAATATACTCACGGCCATTTTG-3'; Lgals1 L3 splice-MO, 5'-
ATGTCTGTACTCACGCATCACAGCC-3'. Before 24 hours post-fertilization (hpf), 1-Phenyl-
2-thiourea (PTU, 0.002%) was added to prevent pigment development. For imaging, 
dechorionated embryos were anesthetized with 0.003% tricaine methanesulfonate and mounted in 
2% low melting agarose. Confocal scanning microscopy was performed using a Leica TCS NT.  
For whole mount blood staining, dechorionated and PTU treated embryos were incubated in 40% 
EtOH, 0.01M NaAc pH5.2, 2.0% H2O2, in the presence of 0.8 mg/ml o-dianisidine. Following 
rehydration in a graded series of EtOH/PBST the embryos were stored in 50% glycerol at 4°C. 
Whole mount in situ hybridization on zebrafish embryos was carried out as previously described 
(44). For VE-cadherin riboprobe synthesis we used the previously published plasmid (45). For 
Lgals1-L2 antisense probe synthesis RZPD clone IMAGp998D0710947Q3 (in pSPORT1) was 
linearized with BamHI and transcribed with T7 RNA polymerase. Zebrafish Lgals1-L3 was 
cloned from RZPD clone IMAGp998J1712051Q3 into pBluescript KS giving rise to lgal1-
L3/pBs. For lgal1-L3 antisense probe synthesis, plasmid lgal1-L3/pBs was linearized with 
Acc65I and transcribed with T7 RNA polymerase. For sectioning, the embryos were embedded 
in Technovit 8100 (Heraeus Kulzer, Wehrheim Germany). Seven µM thick sections were cut and 




All data are shown as mean with standard error except where indicated otherwise. Data from in 
vitro proliferation, real-time PCR, CAM assay, FACS analysis, and CD45/CD8 scores were 
analyzed using the Mann-Whitney U test. Tumor growth curves and migration assay data were 
analyzed using 2-way ANOVA. The Student's t-test was used to analyze the vascular parameters. 
All values are two-sided and P-values<0.05 were considered statistically significant. Two-way 
ANOVA was performed in Graphpad Prism 3.0 (Graphpad Software Inc.). All other statistical 
computations were performed in SPSS 10.0.5. (SPSS Inc.). 
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Figure 1. Galectin-1 binds to anginex and galectin-1 expression is enhanced in activated EC 
and tumor EC; role in EC function. 
(A) Immunohistochemical detection of anginex treated HUVEC using mouse monoclonal 2D10 
anti-anginex antibody (red staining) in a time-lapse experiment. Nuclei are counterstained with 
DAPI (blue staining). Anginex appears in vesicular structures (arrowheads). In the control, the 
primary antibody was omitted. Bar in the left panel represents 10 μm. (B) Electron microscopy of 
an immunogold labeling of anginex demonstrating the accumulation of anginex in HUVEC. 
Inset: Detail showing the membrane localization of anginex (arrowheads). Magnification: 
80,500x. (C) Gal-1 is overexpressed in EC of human colon carcinoma and Ewing sarcoma as 
compared to normal human colon. The top panels show a double staining for the EC (CD31/34, 
blue) and the proliferation marker Ki67 (brown/black). The lower panels show staining of a 
consecutive section for gal-1 (brown) with hematoxylin as counterstain (blue). The arrows 
indicate blood vessels. Arrowheads point towards individual proliferating EC. The insets show a 
detail of gal-1 staining in EC (arrow). (D) Gal-1 mRNA (qPCR; n=5) and protein (FACS; n=4) 
expression are upregulated in activated HUVEC. Expression was determined in cells immediately 
following isolation from the umbilical vein (native) and after culturing the cells for three 
additional days in medium containing 20% human serum (active). *p<0.05. vs. native. (E) 
Knockdown of gal-1 expression with ODN results in a concentration dependent inhibition of EC 
proliferation (n=4); *p<0.05 vs. control; #p<0.05 vs. control ODN. (F) Treatment with 1 µM or 5 
µM gal-1 ODN results in a significant inhibition of EC migration (n=4); #p<0.005 vs. blank; 
*p<0.05 vs. blank. (G) Treatment with a gal-1 antibody results in a significant inhibition of EC 
migration (n=3); #p<0.005 vs. PBS; *p<0.01 vs. PBS. 
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Figure 2. Expression of zebrafish Lgals-1 L2 and Lgals-1 L3. 
Whole mount in situ hybridization on 48h zebrafish embryos. (A) Lgals-1 L2 is strongly 
expressed in the eyes around the lens (arrow) and in the ventricular zone in the head 
(arrowheads). (B) Lgals-1 L3 expression is less restricted but does overlap with L2 expression 
around the lens (arrow) and in the ventricular zone (arrow heads). (C-E) Cross sections at the 
level of the midbrain of whole mount in situ hybridizations of (C) Lgals-1 L2 (inset is 
photographed from more anterior section), (D) Lgals-1 L3, and (E) VE-cadherin. Expression of 
both Lgals-1 L2 and L3 is observed in blood vessels in the brain (arrowhead in C and D) and in 
the retinal vessels (arrow in C and D) and colocalizes with the expression of EC marker VE-
cadherin.  
 
Figure 3. Loss of zebrafish galectin-1 L2 and L3 results in hemorrhages in the brain and 
defective vessel formation. 
(A-D) o-Dianisidine staining for hemoglobin on 2.5 dpf embryos. (A) wild type control or 
injected with (B) Lgals1 L2 AT-MO, (C) Lgals-1 L3 ATG-MO, (D) both Lgals-1 L2 and L3 
ATG-MOs. Co-injection of L2 and L3 ATG-MO results in severe hemorrhaging in the brain 
region (arrowheads). Arrow in (A) shows blood accumulating on the yolk and in the heart of a 
control embryo. (E) Schematic drawing of blood vessels in the dorsal brain at 2.5 dpf (modified 
from (46)). (F-H) Projection of Z-stacks made by confocal microscopy from Tg(fli1:egfp)y1 
transgenic embryos at the level of the dorsal brain vessels at 2.5 dpf. (F) wild type control 
embryo. (G) Embryos co-injected with Lgals-1 L2 and -L3 ATG-MO display aberrant sprouting 
and misguidance of the middle cerebral vein (MCeV) into the dorsal longitudinal vein (DLV) 
(arrowheads). Defective angiogenic sprouting is also observed in the mesencephalic vein (arrow). 
(H) Co-injection of the Lgals-1 L2 and L3 splice-MO shows similar defects in angiogenic 
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sprouting of the brain vessels. DLV, dorsal longitudinal vein; MCeV, middle cerebral vein; MsV 
mesencephalic vein; MtA, metencephalic artery; PCeV, posterior cerebral vein. 
 
Figure 4. Hampered tumor growth and lack of responsiveness to anginex in galectin-1 
deficient mice. 
(A) F9 teratocarcinoma tumor growth in gal-1+/+ (solid squares) and gal-1-/- (solid triangles) mice. 
#p<0.001. (B) Immunohistochemical evaluation of vasculature and gal-1 expression in tumors 
from gal-1+/+ (upper panels) and gal-1-/- (lower panels) mice. The left panels show vessel staining 
with EC marker 9F1 (brown). In the right panel, gal-1 staining (brown) is shown in consecutive 
sections. Bars represents 20 µm. (C) Quantification of microvessel density (MVD) in tumors 
from gal-1+/+ (black bars) and gal-1-/- (white bars) mice. *p<0.001 vs. wild type mice. (D) F9 
teratocarcinoma tumor growth in gal-1+/+ mice during treatment with PBS (solid squares) or 
anginex (open squares). #p<0.001 vs. control. (E) Quantification of microvessel density (MVD) 
in gal-1+/+ mice after treatment with PBS or anginex. *p<0.05 vs. untreated. (F) F9 
teratocarcinoma tumor growth in gal-1-/- during treatment with PBS (filled triangles) or anginex 













 Multiple screens against cDNA libraries of activated EC identified galectin-1 (gal-1) 
as the receptor for anginex (Suppl. Table 1). Galectin-1 was found most frequently (15%) 
while no other members of the galectin family were identified. The identification of 
fibronectin, of which a previous study reported that it facilitates transport of anginex to the 
tumor vasculature (1), confirmed the validity of the approach.   
 The interaction was confirmed using three approaches i) Double staining of anginex 
treated EC showed co-localization of anginex and gal-1 (Suppl. Fig. 1A). ii) Analysis of 
NMR spectra revealed chemical shift changes of certain resonances from gal-1 upon addition 
of anginex, indicative of a specific molecular interaction (Suppl. Fig. 1B). iii) Plasmon 
resonance spectroscopy (BIAcore analysis) was used to further define the kinetics and 
stoichiometry of the interaction. To that end, gal-1 was immobilized on a BIAcore sensor chip 
which was verified with a rabbit polyclonal anti-gal-1 antibody (Suppl. Fig. 1C). Addition of 
anginex resulted in a concentration dependent change in resonance response units (Suppl. 
Fig. 1D). Analysis of the binding kinetics revealed a 1:1 Langmuir association with a rate 
constant (ka) of ~6.5x103 Ms-1, while the dissociation kinetics followed a biphasic pattern 
with dissociation rate constants of 4.2x10-2 s-1 and 5.9x10-4 s-1, respectively (Suppl. Fig. 
1E).  
 The in vivo role of gal-1 in angiogenesis was studied in the chick chorioallantoic 
membrane (CAM). Treatment of the CAM with a rabbit polyclonal anti-gal-1 antibody 
induced a significant inhibition of microvessel density, similar as previously published for 
anginex albeit less pronounced (Suppl. Fig. 2A). Interestingly, treatment caused tortuous and 
irregular growth of the vessels, suggesting a defect in vascular guidance (Suppl. Fig. 2B). 
 In the tumors of gal-1 null mice, several parameters of vessel architecture were 
decreased, indicative of a less comples and less developed vasculature (Suppl. Table 2). 
Galectin-1 has been shown to mediate apoptosis in activated T cells, which could also 
contribute positively to tumor growth (2). To determine whether this also occurred in our 
tumor model we quantified the amount of peripheral blood leukocytes and the presence of 
CD45+ and CD8+ cells in the tumors. In our teratocarcinoma model there was no significant 
difference in these parameters between gal-1+/+ and gal-1-/- animals (Suppl. Fig. 3) which 
strongly suggests that, in this model, impaired tumor progression in gal-1 null mice largely 
results from decreased angiogenesis. 
In addition, anginex treatment did not significantly affect the number of infiltrating CD45+ or 
CD8+ cells in the tumors of both the wild type and null mice (Suppl. Fig. 4).  
 
 
Materials and Methods 
 
Yeast two-hybrid screening  
Yeast two-hybrid screening was performed using the MATCHMAKER GAL4 Two-Hybrid 
System 3 (Clontech) according to the manufacturers instructions. In short, the artificial 
anginex gene (3) was PCR amplified and cloned into bait vector pGBKT7 in frame with the 
GAL4 DNA binding domain (pBD-Ax). The construct was tested for absence of 
transcriptional activation and toxicity. Subsequently, yeast AH109 cells were co-transformed 
with pBD-Ax, SmaI-linearized prey vector (pGADT7), and a cDNA library which was 
generated from activated HUVEC mRNA. Following growth on media plates selective for 
reporter gene activation, prey plasmids from positive yeast colonies were isolated using 
CHROMA SPIN-1000 columns (Clontech), shuttled into E.Coli, and sequenced using an 
automatic DNA-sequencer (AbiPrism377, Applied Biosystems). Confirmation of interaction 
was performed by targeted transformation of the specific constructs using the small-scale 
yeast transformation protocol as described in the yeast protocol handbook (Clontech). 
 
Surface Plasmon Resonance  
Real-time monitoring of molecular interactions was performed at 25°C using the BIAcore 
1000 biosensor system (BiaCore) according to the manufacturer's instructions. In short, 
recombinant human galectin-1 (4) was immobilized to a CM5 sensor chip (BiaCore) via 
primary amine groups using the Amine Coupling Kit (BiaCore). For interaction analysis, 20 
µl sample was diluted to various concentrations in HBS-EP (Biacore) and was injected using 
the KINJECT command at a flow rate of 30 µl/minute after which the flow cells were 
regenerated by injection of 20 µl regeneration buffer (10 mM glycine-HCl, pH 2.0). 
Association-rate (ka) and dissociation-rate (kd) constants were obtained by analysis of the 
sensograms using the Biaevaluation software, version 3.2. All measurements were performed 
at least in duplicate at all concentrations and the experiment was performed in duplo. 
 
NMR Spectroscopy 
For NMR measurements, 5 mg of recombinant human galectin-1 (4) was dissolved in 600 μl 
of 10mM potassium phosphate buffer made with 95%/5% H2O/D2O at pH 5.2. Freeze-dried 
anginex was dissolved in 10 μl of the same buffer and added to the galectin sample at the 
molar ratio of 1:2 (anginex:galectin). 2D-homonuclear TOCSY spectra (5) with 
WATERGATE for water suppression, were acquired on a Varian UNITY Plus-600 NMR 
spectrometer at 30°C. 2048 complex data points along t2 and 256 increments along t1 
dimensions over a spectral width of 9000 Hz, were collected. A mixing time of 50 ms was 
used. Data were processed using a Gaussian window function and the program NMRPipe (6).  
 Electron Microscopy 
For electron microscopy, HUVEC were grown on gelatin coated and glutaraldehyde fixed 
thermanox cover slips in normal HUVEC culture medium supplemented with 75 µM anginex. 
Subsequently, cells were fixed with 1% paraformaldehyde, and localization of anginex by jet 
freezing and freeze substitution was performed as described previously (7), using polyclonal 
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Supplementary Table 1. Results of yeast two-hybrid screening with anginex as bait. 
Clone name number of clones 
Galectin-1 9 
Methallothionein 2A 3 
Fibronectin (partial) 3 
Pecanex-like3 3 
Keratin 2 
Filamin A 1 
GCN1 1 
Methyltransferase 1 
False positivesa 23 
Undeterminedb 14 
Total 60 
a Failed to show interaction following repeated plating or high selection plates or in targeted 
yeast transformation (see Materials & Methods). 















gal-1+/+ 8642 ± 666 147 ± 11 10 ± 1.1 11.6 ± 1.0 
gal-1-/- 2009 ± 269# 48.8 ± 3.4# 2.0 ± 0.6# 2.8 ± 0.3#
On the last day of the experiment, tumors were excised. Tumors without apparent widespread 
necrosis were embedded in tissue freezing medium (Miles Inc.) and snap frozen in liquid 
nitrogen. Preparation and procedures were done as described earlier(8). 
a After binarization of the images from CD31-staining, microvessel density was estimated by 
scoring the total number of white pixels per field.  
b Mean number of vessel end points as determined after skeletonization of the images(8). 
c Mean number of vessel branch points/nodes per image.  
d Mean total vessel length per image.  
All results are expressed as mean pixel counts per image ± standard error from 20 images. 





Supplementary figure legends 
 
Supplementary Figure 1. Confirmation and characterization of the interaction between 
galectin-1 and anginex. 
(A) Fluorescence double staining of anginex (red) and galectin-1 (green) in anginex treated 
EC. Co-localization (yellow) is indicated with arrow heads. Nuclei are counterstained with 
DAPI. Bar in the left panel represents 10 µm (B) NMR analysis of the galectin-1/anginex 
interaction. The Hα - NH fingerprint region is shown from 2D TOCSY spectra of pure 
galectin-1 (red) and of galectin-1 to which anginex was added (blue) at a molar ratio of 1:2 
(anginex:galectin-1). Single color signals and incomplete overlapping color signals indicate a 
shift in resonances upon addition of anginex and are indicative of galectin-1/anginex 
interactions. (C) Validation of galectin-1 immobilization on a BIAcore sensor chip and of 
protein preservation with galectin-1 antibody (n=2). Following immobilization of galectin-1, 
increasing amounts of rabbit polyclonal anti-galectin-1 antibody were run over the chip. As 
negative control, rabbit polyclonal anti-anginex antibody was used. (D) Surface plasmon 
resonance analysis of interaction between anginex and galectin-1 (n=3). Increasing amounts 
of anginex were run over the chip with immobilized galectin-1, resulting in an increase in 
response units (RU). (E) Analysis of binding kinetics of interaction between anginex and 
immobilized galectin-1. The upper panel shows a representative dose response sensogram for 
anginex. The areas used for model fitting are shown in bold while the residual plot in the 
middle panel shows minimal discrepancies between the experimental data and the fit. In the 
lower panel the observed association rates (kobs) are plotted as a function of analyte 
concentration with a slope equal to the association rate constant (ka). 
 
 
Supplementary Figure 2. Altered vessel numbers and morphology in chorioallantoic 
membranes after treatment with galectin-1 protein and antibody. 
(A) Quantification of microvessel density in the CAMs after treatment with different dilutions 
of anti-galectin-1 antibody. *p<0.05 vs. control. (B) Representative images of CAMs after 
treatment with PBS (control) and anti-galectin-1 antibody. Note the tortuous and irregular 
growth of the vessels in the latter. 
 
Supplementary Figure 3. The number of circulating leukocytes and tumor infiltrating 
leukocytes is unaltered in galectin-1 mutant mice. 
(A) Immunohistochemical evaluation of tumor infiltrating leukocytes in galectin-1+/+ (upper 
panels) and galectin-1-/- (lower panels) mice. The left panels show CD45+ cells (brown 
staining). In the right panel, CD8+ cells are shown. (B) Quantification of CD45+ and CD8+ 
cells in tumors from galectin-1+/+ (black bars) and galectin-1-/- (white bars) mice. (C) 
Quantification of total number of leukocytes in galectin-1+/+ (black bars) and galectin-1-/- 
(white bars) mice. 
 
Supplementary Figure 4. Anginex treatment does not affect leukocyte infiltration in 
galectin-1 wild type and mutant mice. 
 (A) Immunohistochemical evaluation of infiltrate in untreated tumors from galectin-1+/+ (left 
panels) and in anginex treated tumors from galectin-1+/+ (middle panels) and galectin-1-/- 
(right panels) mice. The upper panels show CD8+ cells (brown staining). In the lower panels, 
CD45+ cells are shown. (B) Quantification of CD45+ and CD8+ cells in untreated tumors from 
galectin-1+/+ (black bars) and  
galectin-1-/- (white bars) as well as in anginex treated tumors from galectin-1+/+ (downward 
diagonal) and galectin-1-/- (upward diagonal) mice. 
Supplementary figure 1 
 
 
Supplementary figure 2 
 
 
Supplementary figure 3 
 
 
Supplementary figure 4 
 
 
 
 
 
 
 
 
 
 
